Neurogene

NGNE · NASDAQ

$25.40+$1.23 (+5.09%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $24.17

NGNE analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $82.04 (+223.0% upside)

Low: $46.46
Now: $25.40
High: $174.30

Upgrades and downgrades

The latest rating actions, newest first

NGNE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 8, 2026	Initiates	Overweight	$60.00	18%
Canaccord Genuity	Aug 12, 2026	Maintains	Buy	$180.00 → $166.00	41%
Guggenheim	Aug 12, 2026	Maintains	Buy	$69.00 → $81.00	45%
HC Wainwright & Co.	Aug 12, 2026	Maintains	Buy	$70.00 → $65.00	32%
HC Wainwright & Co.	Jun 9, 2026	Maintains	Buy	$70.00	32%
Canaccord Genuity	Apr 6, 2026	Maintains	Buy	$200.00 → $180.00	41%
Canaccord Genuity	Feb 27, 2026	Initiates	Buy	$200.00	41%
LifeSci Capital	Jan 26, 2026	Initiates	Outperform	$50.00	75%
HC Wainwright & Co.	Jan 13, 2026	Maintains	Buy	$70.00	32%
HC Wainwright & Co.	Nov 13, 2025	Maintains	Buy	$65.00 → $70.00	32%

The case for and against

Updated Oct 16, 2026

Bull case

Neurogene is supported by a strengthened balance sheet, with $225.4M in cash, cash equivalents and short-term investments at June 30 and about $360.2M pro forma cash after the ~$134.8M net proceeds from the follow-on offering, extending runway into 1Q29. That funding should carry the company beyond Embolden top-line data in 2H27 and through PPQ completion by YE26, reducing financing risk while advancing NGN-401 toward a potential BLA. Fundamentally, the positive view is anchored in NGN-401’s compelling Phase 1/2 efficacy and durability—8/10 patients met the pivotal composite endpoint at 12 months, 10/10 improved on CGI-I and gained milestones, and safety at the 1E15 vg dose has remained supportive across 35 treated patients.

Bear case

Neurogene is facing a highly adverse risk profile because its lead program is exposed to both broad biotech execution hazards and company-specific failures, including development, regulatory, commercial, manufacturing, financing, and IP risk. Safety is especially concerning after cases of HLH/hyperinflammatory syndrome at the current clinical dose of 1E15 vg, while efficacy remains uncertain because the registrational trial could require a 35% response rate versus 80% observed to date. Regulatory and adoption risks further weaken the investment case, as FDA alignment on using the ongoing single-arm EMBOLDEN study for BLA support was reversed and ICV delivery may be a larger barrier than assumed, especially in a non-degenerative disease like Rett syndrome.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.